Sai Parenteral’s IPO was subscribed 1.08 times overall on the last day. A retail quota was subscribed over 0.12 times, NII was subscribed over 2.45 times, and QIB was subscribed over 1.73 times.
Sai Parenteral’s IPO Listing Details
| Listing Date | April 2nd, 2026 |
| BSE Code | – |
| NSE Code | – |
| ISIN Code | – |
| Offer Price | ₹372 to ₹392 |
| Face Value | ₹5 |
| Listing Price | ₹- |
Sai Parenteral’s IPO details
Sai Parenteral’s received SEBI approval for an IPO of ₹409 crores, comprising a fresh issue of ₹285 crores and an OFS of up to 35,00,000 Equity shares with a face value of ₹5 each. The Company has a price band of ₹372 to ₹392 per share.
How many shares did investors receive in this IPO?
Retail minimum investors got 38 shares in 1 lot size.
and for the max retail category, 494 shares in 13 lot sizes.
S-HNI Minimum category, 532 shares in 14, and 2,546 shares in 67 lot sizes in S-HNI Maximum. B-HNI Minimum category, 2,584 shares are available in 68 lot sizes.
To invest in the Sai Parenteral’s IPO, each investor category has specific investment amounts:
- Retail Investors: Minimum investment of ₹14,896.
- Retail investors’ (Max) investment of ₹1,93,648.
- Small HNI (S-HNI): Minimum investment of ₹2,08,544.
- Small HNI (S-HNI): Maximum investment of ₹9,98,032.
- Big HNI(B-HNI): minimum investment of ₹10,12,928.
Sai Parenteral’s IPO Subscription Duration
Sai Parenteral’s IPO subscription started on March 24, 2026, and closed on March 27, 2026. The Sai Parenteral’s IPO allotment date was March 30, 2026, and the refund will be received on April 1, 2026. The Sai Parenteral’s IPO listing is on April 2, 2026.
About the Sai Parenteral’s IPO Company
Founded in 1984, Sai Parenteral is one of the leading pharmaceutical companies that manages everything from research & development to manufacturing of pharmaceutical products. A pharmaceutical brand that not only develops generic medicine for its own brand but also manufactures medicines for other pharmaceutical companies, Sai Parenteral does it all.
Its medicines are available in various forms like tablets, injections, and syrups. Sai Parenteral’s major clients are government agencies, pharmaceutical companies, public and private hospitals, and large distributors in India.
Its product offerings include a wide range of medicines for various health conditions, like cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals, and supplements (VMS), analgesics, and dermatology. The firm operates 5 manufacturing facilities in India, mainly located in Hyderabad, known for developing medicines with international quality certifications.
Sai Parenteral’s IPO Company Financial Report
The company reported revenue of ₹163.74 crores in 2025 against ₹155.18 crores in 2024. The company reported a profit of ₹14.43 crores in 2025 against a profit of ₹8.42 crores in 2024.
